This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Barrett, C. M. Articles by Lothstein, L. Search for Related Content PubMed PubMed Citation Articles by Barrett, C. M. Articles by Lothstein, L.

Department of Pharmacology, The University of Tennessee Health Science Center, Memphis, Tennessee 38163 [C. M. B., F. L. L., J. B. R., T. W. S., M. I., L. L.], and Department of Biochemistry, St. Jude Children’s Research Hospital, Memphis, Tennessee 38105 [J. L. C.]

Bcl-2 inhibits apoptosis induced by numerous antitumor drugs, including doxorubicin and daunorubicin and is, thus, a major impediment to successful cancer chemotherapy. Here, we report the ability of a novel family of nonnuclear targeted anthracyclines to induce rapid apoptosis in cells despite Bcl-2 or Bcl-X_L expression. Typified by N-benzyladriamycin-14-valerate (AD 198) and N-benzyladriamycin-14-pivalate (AD 445), this family of compounds binds to the C1 regulatory domain of protein kinase C (PKC), competitively inhibits phorbol ester binding in cell-free studies, and induces PKC translocation in intact cells. PKC- has an established role as a pro-apoptotic protein through the association of the holoenzyme or catalytic fragment with mitochondria. In proliferating 32D.3 myeloid cells, or in 32D.3 cells engineered to overexpress Bcl-2, substantial levels of PKC- are associated with mitochondria. However, after a 1-h exposure to 5 µM AD 198, cytochrome c release, caspase-3 activation, poly(ADP-ribose) polymerase (PARP) cleavage, PKC- cleavage, and DNA fragmentation are observed. Pretreatment of 32D.3 cells with the selective PKC- inhibitor, rottlerin, but not the general PKC inhibitor, GF 109203X, or PKC- and -ß inhibitor, Gö 6976, delayed the 50% cell kill to >24 h for control and Bcl-2 overexpressing 32D.3 cells treated with 5 µM AD 198. Rottlerin delayed PKC- and PARP cleavage to >20 h post-drug exposure and also delayed mitochondrial membrane depolarization. In contrast, the pan-caspase inhibitor Z-Val-Ala-Asp-CH₂F blocked PKC- and PARP cleavage, but not mitochondrial membrane depolarization. These results suggest that AD 198 induces mitochondrial-dependent apoptosis in 32D.3 cells by activating PKC- holoenzyme on mitochondria, which, in turn, overrides the antiapoptotic effects of Bcl-2.

This article has been cited by other articles:

				P. A. Hofmann, M. Israel, Y. Koseki, J. Laskin, J. Gray, A. Janik, T. W. Sweatman, and L. Lothstein N-Benzyladriamycin-14-valerate (AD 198): A Non-Cardiotoxic Anthracycline That Is Cardioprotective through PKC-{epsilon} Activation J. Pharmacol. Exp. Ther., November 1, 2007; 323(2): 658 - 664. [Abstract] [Full Text] [PDF]

				W. Zang, S. Kalache, M. Lin, B. Schroppel, and B. Murphy MHC Class II-Mediated Apoptosis by a Nonpolymorphic MHC Class II Peptide Proceeds by Activation of Protein Kinase C J. Am. Soc. Nephrol., December 1, 2005; 16(12): 3661 - 3668. [Abstract] [Full Text] [PDF]

				Y. He, J. Liu, D. Durrant, H.-S. Yang, T. Sweatman, L. Lothstein, and R. M. Lee N-Benzyladriamycin-14-Valerate (AD198) Induces Apoptosis through Protein Kinase C-{delta}-Induced Phosphorylation of Phospholipid Scramblase 3 Cancer Res., November 1, 2005; 65(21): 10016 - 10023. [Abstract] [Full Text] [PDF]

				G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity Pharmacol. Rev., June 1, 2004; 56(2): 185 - 229. [Abstract] [Full Text] [PDF]

				J. D. Bilyeu, G. R. Panta, L. G. Cavin, C. M. Barrett, E. J. Turner, T. W. Sweatman, M. Israel, L. Lothstein, and M. Arsura Circumvention of Nuclear Factor {kappa}B-Induced Chemoresistance by Cytoplasmic-Targeted Anthracyclines Mol. Pharmacol., April 1, 2004; 65(4): 1038 - 1047. [Abstract] [Full Text]

				Y.-M. Ham, J.-S. Choi, K.-H. Chun, S.-H. Joo, and S.-K. Lee The c-Jun N-terminal Kinase 1 Activity Is Differentially Regulated by Specific Mechanisms during Apoptosis J. Biol. Chem., December 12, 2003; 278(50): 50330 - 50337. [Abstract] [Full Text] [PDF]

				J. B. Roaten, M. G. Kazanietz, M. J. Caloca, P. J. Bertics, L. Lothstein, A. L. Parrill, M. Israel, and T. W. Sweatman Interaction of the Novel Anthracycline Antitumor Agent N-Benzyladriamycin-14-valerate with the C1-Regulatory Domain of Protein Kinase C: Structural Requirements, Isoform Specificity, and Correlation with Drug Cytotoxicity Mol. Cancer Ther., May 1, 2002; 1(7): 483 - 492. [Abstract] [Full Text] [PDF]